Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2

Wylie Burke, Mary Daly, Judy Garber, Jeffrey Botkin, Mary Jo Ellis Kahn, Patrick Lynch, Anne McTiernan, Kenneth Offit, Jeffrey Perlman, Gloria M Petersen, Elizabeth Thomson, Claudette Varricchio

Research output: Contribution to journalArticle

845 Citations (Scopus)

Abstract

Objective. - To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. Participants. - A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence. - Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were 'genetics' in combination with 'breast cancer,' 'ovarian cancer,' and 'screening,' or 'surveillance' in combination with 'cancer family' and 'BRCA1' and 'BRCA2.' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process. - The task force developed recommendations through discussions over a 14-month period. Conclusions. - Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, and case reports have documented the occurrence of cancer following prophylactic surgery. It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.

Original languageEnglish (US)
Pages (from-to)997-1003
Number of pages7
JournalJournal of the American Medical Association
Volume277
Issue number12
StatePublished - Mar 26 1997
Externally publishedYes

Fingerprint

Aftercare
Mutation
National Human Genome Research Institute (U.S.)
Neoplasms
Advisory Committees
Early Detection of Cancer
Ovarian Neoplasms
Breast Neoplasms
Risk Reduction Behavior
BRCA2 Gene
National Library of Medicine (U.S.)
BRCA1 Gene
Medical Oncology
Mastectomy
Medical Genetics
Expert Testimony
Bibliography
Genetic Testing
Ovariectomy
Gastroenterology

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Burke, W., Daly, M., Garber, J., Botkin, J., Kahn, M. J. E., Lynch, P., ... Varricchio, C. (1997). Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Journal of the American Medical Association, 277(12), 997-1003.

Recommendations for follow-up care of individuals with an inherited predisposition to cancer : II. BRCA1 and BRCA2. / Burke, Wylie; Daly, Mary; Garber, Judy; Botkin, Jeffrey; Kahn, Mary Jo Ellis; Lynch, Patrick; McTiernan, Anne; Offit, Kenneth; Perlman, Jeffrey; Petersen, Gloria M; Thomson, Elizabeth; Varricchio, Claudette.

In: Journal of the American Medical Association, Vol. 277, No. 12, 26.03.1997, p. 997-1003.

Research output: Contribution to journalArticle

Burke, W, Daly, M, Garber, J, Botkin, J, Kahn, MJE, Lynch, P, McTiernan, A, Offit, K, Perlman, J, Petersen, GM, Thomson, E & Varricchio, C 1997, 'Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2', Journal of the American Medical Association, vol. 277, no. 12, pp. 997-1003.
Burke, Wylie ; Daly, Mary ; Garber, Judy ; Botkin, Jeffrey ; Kahn, Mary Jo Ellis ; Lynch, Patrick ; McTiernan, Anne ; Offit, Kenneth ; Perlman, Jeffrey ; Petersen, Gloria M ; Thomson, Elizabeth ; Varricchio, Claudette. / Recommendations for follow-up care of individuals with an inherited predisposition to cancer : II. BRCA1 and BRCA2. In: Journal of the American Medical Association. 1997 ; Vol. 277, No. 12. pp. 997-1003.
@article{d85ac41b7bb54aa5b143dcd05ad85dc2,
title = "Recommendations for follow-up care of individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2",
abstract = "Objective. - To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. Participants. - A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence. - Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were 'genetics' in combination with 'breast cancer,' 'ovarian cancer,' and 'screening,' or 'surveillance' in combination with 'cancer family' and 'BRCA1' and 'BRCA2.' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process. - The task force developed recommendations through discussions over a 14-month period. Conclusions. - Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, and case reports have documented the occurrence of cancer following prophylactic surgery. It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.",
author = "Wylie Burke and Mary Daly and Judy Garber and Jeffrey Botkin and Kahn, {Mary Jo Ellis} and Patrick Lynch and Anne McTiernan and Kenneth Offit and Jeffrey Perlman and Petersen, {Gloria M} and Elizabeth Thomson and Claudette Varricchio",
year = "1997",
month = "3",
day = "26",
language = "English (US)",
volume = "277",
pages = "997--1003",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "12",

}

TY - JOUR

T1 - Recommendations for follow-up care of individuals with an inherited predisposition to cancer

T2 - II. BRCA1 and BRCA2

AU - Burke, Wylie

AU - Daly, Mary

AU - Garber, Judy

AU - Botkin, Jeffrey

AU - Kahn, Mary Jo Ellis

AU - Lynch, Patrick

AU - McTiernan, Anne

AU - Offit, Kenneth

AU - Perlman, Jeffrey

AU - Petersen, Gloria M

AU - Thomson, Elizabeth

AU - Varricchio, Claudette

PY - 1997/3/26

Y1 - 1997/3/26

N2 - Objective. - To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. Participants. - A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence. - Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were 'genetics' in combination with 'breast cancer,' 'ovarian cancer,' and 'screening,' or 'surveillance' in combination with 'cancer family' and 'BRCA1' and 'BRCA2.' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process. - The task force developed recommendations through discussions over a 14-month period. Conclusions. - Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, and case reports have documented the occurrence of cancer following prophylactic surgery. It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.

AB - Objective. - To provide recommendations for cancer surveillance and risk reduction for individuals carrying mutations in the BRCA1 or BRCA2 genes. Participants. - A task force with expertise in medical genetics, oncology, primary care, gastroenterology, and epidemiology convened by the Cancer Genetics Studies Consortium (CGSC), organized by National Human Genome Research Institute (previously the National Center for Human Genome Research). Evidence. - Studies evaluating cancer risk, surveillance, and risk reduction in individuals genetically susceptible to breast and ovarian cancer were identified using MEDLINE (National Library of Medicine) and from bibliographies of articles thus identified. Indexing terms used were 'genetics' in combination with 'breast cancer,' 'ovarian cancer,' and 'screening,' or 'surveillance' in combination with 'cancer family' and 'BRCA1' and 'BRCA2.' For studies evaluating specific interventions, quality of evidence was assessed using criteria of the US Preventive Services Task Force. Consensus Process. - The task force developed recommendations through discussions over a 14-month period. Conclusions. - Efficacy of cancer surveillance or other measures to reduce risk in individuals who carry cancer-predisposing mutations is unknown. Based on expert opinion concerning presumptive benefit, early breast cancer and ovarian cancer screening are recommended for individuals with BRCA1 mutations and early breast cancer screening for those with BRCA2 mutations. No recommendation is made for or against prophylactic surgery (eg, mastectomy, oophorectomy); these surgeries are an option for mutation carriers, but evidence of benefit is lacking, and case reports have documented the occurrence of cancer following prophylactic surgery. It is recommended that individuals considering genetic testing be counseled regarding the unknown efficacy of measures to reduce risk and that care for individuals with cancer-predisposing mutations be provided whenever possible within the context of research protocols designed to evaluate clinical outcomes.

UR - http://www.scopus.com/inward/record.url?scp=0030893779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030893779&partnerID=8YFLogxK

M3 - Article

C2 - 9091675

AN - SCOPUS:0030893779

VL - 277

SP - 997

EP - 1003

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 12

ER -